Literature DB >> 30430317

Intrathecal nusinersen treatment for SMA in a dedicated neuromuscular clinic: an example of multidisciplinary and integrated care.

Valeria A Sansone1, Emilio Albamonte2, Francesca Salmin2, Jacopo Casiraghi2, Alice Pirola2, Massimo Bettinelli2, Fabrizio Rao2, Luca Mancini3, Nicola Tovaglieri3, Fausto Fedeli3, Paolo Stoia3, Maurizio Heinen3, Valeria Cozzi3, Elena Carraro2, Christian Lunetta2, Alessandra Di Bari2, Eugenio Mercuri4.   

Abstract

Nusinsersen is now available in Italy for all SMA types. We describe the experience with intrathecal treatment with nusinersen in 50 patients with SMA at the NEMO Center (NEuroMuscular Omniservice Clinical Center) in Milan, a neuromuscular patient-centered clinic hosted within Niguarda Hospital, a National Public General Hospital. Our results indicate that the pathway of care described outweighs the burden due to the repeated intrathecal injections. Irrespective of age and severity, the treatment is feasible, accessible, and replicable provided that there is a multidisciplinary team having experience and training in SMA.

Entities:  

Keywords:  Integrated care; Multidisciplinary; Nusinersen; Spinal muscular atrophy; Spinraza

Mesh:

Substances:

Year:  2018        PMID: 30430317     DOI: 10.1007/s10072-018-3622-9

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  6 in total

1.  Rare Neurologic Diseases and Neurological Sciences: a report for the celebration of the 2020 Rare Diseases Day.

Authors:  Antonio Federico
Journal:  Neurol Sci       Date:  2020-03       Impact factor: 3.307

2.  Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy.

Authors:  Alma Osmanovic; Gresa Ranxha; Susanne Petri; Olivia Schreiber-Katz; Mareike Kumpe; Lars Müschen; Camilla Binz; Flavia Wiehler; Lejla Paracka; Sonja Körner; Katja Kollewe
Journal:  J Neurol       Date:  2020-05-02       Impact factor: 4.849

3.  An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials.

Authors:  Basil T Darras; Michelle A Farrar; Eugenio Mercuri; Richard S Finkel; Richard Foster; Steven G Hughes; Ishir Bhan; Wildon Farwell; Sarah Gheuens
Journal:  CNS Drugs       Date:  2019-09       Impact factor: 5.749

4.  Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy.

Authors:  Alma Osmanovic; Gresa Ranxha; Mareike Kumpe; Claudia D Wurster; Benjamin Stolte; Isabell Cordts; René Günther; Maren Freigang; Lars H Müschen; Camilla Binz; Andreas Hermann; Marcus Deschauer; Paul Lingor; Albert C Ludolph; Tim Hagenacker; Olivia Schreiber-Katz; Susanne Petri
Journal:  Ther Adv Neurol Disord       Date:  2021-03-05       Impact factor: 6.570

5.  Brain Awareness Week, CoVID-19 infection and Neurological Sciences.

Authors:  Antonio Federico
Journal:  Neurol Sci       Date:  2020-04       Impact factor: 3.307

6.  Experiences from treating seven adult 5q spinal muscular atrophy patients with Nusinersen.

Authors:  Elisabeth Jochmann; Robert Steinbach; Thomas Jochmann; Ha-Yeun Chung; Annekathrin Rödiger; Rotraud Neumann; Thomas E Mayer; Klaus Kirchhof; Dana Loudovici-Krug; Ulrich C Smolenski; Otto W Witte; Julian Grosskreutz
Journal:  Ther Adv Neurol Disord       Date:  2020-03-05       Impact factor: 6.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.